Attovia (ATTO) 10% Owner venBio Fund IV Buys 382,352 Shares

What Happened

• venBio Global Strategic Fund IV, L.P. (a 10% owner of Attovia Therapeutics, ticker ATTO) reported an open‑market purchase of 382,352 common shares on August 6, 2026 at $17.00 per share, totaling $6,499,984.
• The Form 4 also shows multiple conversions of derivative securities (preferred stock converting into common stock) on the same date: three conversion line items recorded as acquisitions totaling 3,799,015 shares (2,311,870; 821,998; 665,147) and three conversion line items recorded as dispositions totaling 35,292,854 shares (21,477,273; 7,636,362; 6,179,219). These conversion entries are recorded at $0 or N/A because they reflect automatic conversion events rather than cash transactions.

Key Details

• Transaction date: August 6, 2026; Form 4 filed August 10, 2026 (appears to be filed within the required reporting window).
• Open‑market purchase: 382,352 shares @ $17.00 = $6,499,984.
• Derivative conversions: multiple preferred‑to‑common conversions recorded (see counts above); conversion entries show $0 price per footnote.
• Footnote F1: Series A/B/C Preferred automatically converted one‑for‑one into common stock on completion of the issuer's IPO, adjusted for a 1‑for‑9.29 reverse split effected July 29, 2026.
• Footnote F2: Securities are held directly by venBio Global Strategic Fund IV, L.P.; the Fund’s general partner and its members disclaim beneficial ownership under the rule of three — this is institutional trading, not an individual executive transaction.
• Shares owned after the transactions are not specified in the excerpt of the filing provided.

Context

• The $6.5M open‑market purchase is a clear, cash purchase (a stronger signal for investors than routine insider sales), while the large conversion entries reflect the automatic conversion of preferred shares into common stock in connection with Attovia's IPO and reverse split — these are bookkeeping/conversion events rather than market sales.
• Because venBio is a 10% institutional owner and the general partner disclaims personal beneficial ownership, this filing mainly documents the fund’s holdings and conversion events rather than a vote of confidence by a corporate insider.